Hippocampal sclerosis

Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients

Retrieved on: 
Thursday, November 2, 2023
Health, Neurology, Research, Pharmaceutical, Science, Biotechnology, Alzheimer's disease, Plasma, AFL, PD, Duarte de Meneses, 3rd Count of Viana, Biomarker, Level, Human, Pathology, Hippocampal sclerosis, Inflammation, Huntingtin, Goate, Mitchell, Dave Senjem, Mitsutake Hikoshichi, White, TAR, Disease, A, GFAP, Nerve, PMCID, S, PMID, Frontotemporal lobar degeneration, Patient, Experimental & Molecular Medicine, YM, Parkinson's disease, Whitwell, Dietary supplement, Medical imaging, Hospital, TDP43

“We are pleasantly surprised to see a statistically significant drop in TDP43 levels in just 10 patients and to see a strong trend in GFAP and NfL.

Key Points: 
  • “We are pleasantly surprised to see a statistically significant drop in TDP43 levels in just 10 patients and to see a strong trend in GFAP and NfL.
  • To our knowledge this is the first time that a drug reduces the levels of TDP43 in humans, specifically here in PD patients,” said Dr. Maccecchini.
  • “These biomarker data not only corroborate the mechanism of actions of buntanetap, but also provide a new way to stratify patients and understand their disease pathology.
  • TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration.

Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.

Retrieved on: 
Tuesday, November 22, 2022
Hypersensitivity, Kidney, Multiple system atrophy, Risk, Defecation, Pregnancy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Birth, Miscarriage, Iodine, Itch, PSP, Dizziness, Urination, Dementia, Lactation, Alzheimer's disease, Placenta, Nausea, Breast milk, Caregiver, Patient, Radiation, Vertigo, Thyroid, Frontotemporal dementia, Medicine, SPECT, FDA, Diagnosis, Degenerative disease, PET, Food, DLB, Nuclear medicine, Disease, Radiopharmaceutical, Failure, Neoplasm, Safety, Headache, Dopamine, Administration, Milk, Hippocampal sclerosis, GE, Scan (company), Regulation, MSA, Injection, PD, Lewy body, Tremor, Xerostomia, Excipient, Infant, Medical imaging, Pharmaceutical industry, Vaccine, Birth control, Ioflupane (123I), Parkinsonism, PS

Curium will update Ioflupane I 123 Injection important risk information to include the new safety information at the time of labeling implementation.

Key Points: 
  • Curium will update Ioflupane I 123 Injection important risk information to include the new safety information at the time of labeling implementation.
  • The expected new indication enables clinicians to use Ioflupane I 123 Injection to help differentiate DLB from other forms of dementia.
  • Curium has years of experience in this disease state as our Ioflupane I 123 Injection product in Europe launched with this indication.
  • The kidney excretes Ioflupane I 123 Injection; patients with severe renal impairment may have increased radiation exposure and altered Ioflupane I 123 Injection images
    It is unknown whether or not ioflupane is dialyzable.